Sponsor or institution

Clinical trials and research at Canadian Cancer Trials Group

• 27Clinical trials
• 11Countries

Newest trials

All recruiting trials (27)

• Asking people in CCTG cancer trials about social, economic, and environmental factors

  This project asks adults in Canadian Cancer Trials Group (CCTG) cancer trials to fill a short questionnaire to see if patients are willing to share social, economic, and environmental information that affects health.

  Recruiting at 15 sites Canadian Cancer Trials Group · Calgary, Alberta and 14 other locations · NCT07390435

• Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

  This trial tests whether adding two oral drugs, sonrotoclax and zanubrutinib, to standard CAR-T therapy helps people with mantle cell lymphoma who have relapsed or are refractory after prior treatment.

  Recruiting at 5 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 4 other locations · NCT07341191

• GCAR1 CAR-T therapy for GPNMB-expressing solid tumours

  This study tests different doses of GCAR1 CAR-T cells in people with specific cancers that make high levels of the GPNMB protein to see if the treatment is safe and how it affects the cancer.

  Recruiting at 3 sites Phase 1 Canadian Cancer Trials Group · Calgary, Alberta and 3 other locations · NCT07297667

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Targeted radiotherapy to control limited progression in metastatic non-small cell lung cancer

  This study will try adding focused high-dose radiotherapy (SBRT) to standard immunotherapy or chemo-immunotherapy for people with metastatic non-small cell lung cancer who have a few sites starting to grow (oligoprogression).

  Recruiting at 75 sites Phase 3 Canadian Cancer Trials Group · Phoenix, Arizona and 74 other locations · NCT06686771

• Comparing two types of radiation therapy for advanced head and neck cancer

  This study tests if a new type of radiation therapy called SBRT can help people with advanced head and neck cancer better than the standard radiation treatment.

  Recruiting at 10 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 9 other locations · NCT06641791

• Using LND101 with Immunotherapy for Advanced Melanoma

  This study is testing if adding a gut treatment called LND101 to standard immunotherapy can help people with advanced melanoma have better outcomes.

  Recruiting at 15 sites Phase 2 Canadian Cancer Trials Group · Abbotsford British Columbia, British Columbia and 14 other locations · NCT06623461

• Adding docetaxel to hormone and androgen-blocking therapy for men with metastatic prostate cancer who have a weak PSA response

  This trial tests whether adding docetaxel to standard hormone and androgen-blocking therapy helps men with metastatic, castration-sensitive prostate cancer who still have a higher-than-expected PSA after 6–12 months of treatment.

  Recruiting at 380 sites Phase 3 Canadian Cancer Trials Group · Anchorage, Alaska and 394 other locations · NCT06592924

• Combining carboplatin with docetaxel for advanced prostate cancer treatment

  This study is testing if adding carboplatin to the usual treatment of docetaxel can help people with advanced prostate cancer by slowing down the growth or spread of their disease.

  Recruiting at 14 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 13 other locations · NCT06439225

• Comparing two types of radiation therapy for painful bone metastases

  This study is testing whether a new type of radiation therapy can help people with painful bone cancer feel better than the standard treatment.

  Recruiting at 12 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 11 other locations · NCT06391242

• Assessing treatment needs for early-stage vulvar cancer based on HPV and p53 status

  This study is testing if early-stage vulvar cancer patients need different treatments based on whether their cancer is linked to HPV or not.

  Recruiting at 12 sites Canadian Cancer Trials Group · Kelowna, British Columbia and 11 other locations · NCT06358469

• Higher dose radiation therapy for prostate cancer treatment

  This study tests if a higher dose of radiation given in a shorter time can work just as well as the usual treatment for men with tough-to-treat prostate cancer.

  Recruiting at 57 sites Phase 3 Canadian Cancer Trials Group · Antioch, California and 56 other locations · NCT06235697

• Comparing chemotherapy alone versus chemotherapy with radiation for rectal cancer treatment

  This study is testing whether giving chemotherapy alone is just as effective as combining it with radiation for people with early rectal cancer before their surgery.

  Recruiting at 111 sites Phase 3 Canadian Cancer Trials Group · Phoenix, Arizona and 112 other locations · NCT06205485

• Comparing fixed duration and continuous daratumumab treatment for older adults with multiple myeloma

  This study is testing if older adults with newly diagnosed multiple myeloma can stop daratumumab treatment after 18-20 cycles and still get similar benefits as those who keep taking it continuously.

  Recruiting at 31 sites Phase 3 Canadian Cancer Trials Group · Edmonton, Alberta and 30 other locations · NCT06182774

• Combining zanidatamab with standard treatment for advanced HER2 positive gastroesophageal cancer

  This study is testing if adding a new drug called zanidatamab to standard treatments can help people with advanced HER2 positive gastroesophageal cancer live longer without their cancer getting worse.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 17 other locations · NCT06043427

• Combining Ibrutinib with standard treatment for patients with primary CNS lymphoma who can't undergo transplant

  This study is testing if combining the drug ibrutinib with standard treatments can help patients with primary CNS lymphoma who can't have a transplant live better and longer.

  Recruiting at 8 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 7 other locations · NCT05998642

• New treatment approach for early-stage endometrial cancer with specific genetic profiles

  This study is testing a new treatment plan for early-stage endometrial cancer patients with specific genetic profiles to see if it works better than the usual treatments.

  Recruiting at 123 sites Phase 2 Canadian Cancer Trials Group · Anchorage, Alaska and 122 other locations · NCT05640999

• Evaluating treatments for resistant metastatic breast cancer using liquid biopsies

  This study is testing if blood tests that look for DNA changes in breast cancer can help doctors figure out which treatments will work best for patients with hard-to-treat metastatic breast cancer.

  Recruiting at 9 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 9 other locations · NCT05601440

• Guided neck treatment for patients with oropharyngeal cancer

  This study is testing if a new targeted neck treatment for oropharyngeal cancer can work as well as the standard method while causing fewer side effects.

  Recruiting at 30 sites Phase 3 Canadian Cancer Trials Group · Corona, California and 37 other locations · NCT05451004

• Comparing early and delayed therapy for high-risk patients with chronic lymphocytic leukemia.

  This study is trying to see if starting treatment right away or waiting longer is better for high-risk patients with chronic lymphocytic leukemia and how it affects their healthcare costs.

  Recruiting at 4 sites Canadian Cancer Trials Group · Vancouver, British Columbia and 5 other locations · NCT05371808

• Comparing new drugs to standard treatment for relapsed Hodgkin lymphoma

  This study is testing if new drugs Pembrolizumab and Brentuximab vedotin work better than standard treatment for people with relapsed Hodgkin lymphoma.

  Recruiting at 18 sites Phase 2 Canadian Cancer Trials Group · Concord, New South Wales and 17 other locations · NCT05180097

• Immunotherapy for advanced ovarian cancer resistant to platinum treatment

  This study tests a new immunotherapy treatment for women with advanced ovarian cancer that hasn’t responded to standard platinum therapy to see if it works better than current options.

  Recruiting at 6 sites Phase 2 Canadian Cancer Trials Group · Chicago, Illinois and 5 other locations · NCT04918186

• A program to support emotional and physical health in patients with acute leukemia

  This study tests if a new support program that includes therapy and symptom checks can help people newly diagnosed with acute leukemia feel better emotionally and physically compared to standard care alone.

  Recruiting at 5 sites Canadian Cancer Trials Group · Saint John, New Brunswick and 5 other locations · NCT04224974

• Treatment with durvalumab for cancer patients who had side effects from previous therapies

  This study is testing if the immunotherapy drug durvalumab, combined with prednisone, can help cancer patients who had side effects from previous treatments while also seeing if it can slow down their cancer.

  Recruiting at 10 sites Phase 2 Canadian Cancer Trials Group · Edmonton, Alberta and 10 other locations · NCT03847649

• Comparing two radiation treatments for brain metastases

  This study is testing whether a new type of targeted radiation treatment works better than a standard whole brain radiation treatment for people with multiple brain tumors.

  Recruiting at 47 sites Phase 3 Canadian Cancer Trials Group · Tucson, Arizona and 85 other locations · NCT03550391

• Targeted therapy for advanced cancers based on genetic profiling

  This study is testing whether targeted treatments based on the genetic makeup of advanced cancers can help patients with conditions like non-Hodgkin lymphoma and multiple myeloma feel better and have more effective options.

  Recruiting at 10 sites Phase 2 Canadian Cancer Trials Group · Edmonton, Alberta and 9 other locations · NCT03297606

• Comparing intermittent and continuous PD-1 inhibitor therapy for metastatic melanoma

  This study is testing if taking a cancer treatment for melanoma continuously or with breaks works just as well for patients and if the break approach might have fewer side effects.

  Recruiting at 30 sites Phase 3 Canadian Cancer Trials Group · Victoria, Mildura and 29 other locations · NCT02821013

Quick answers

How many clinical trials run by Canadian Cancer Trials Group are recruiting right now?

27, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in Canada (27 trials), United States (8 trials), Australia (3 trials), New Zealand (2 trials), Mexico (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 3: 11, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →